Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Weiz

435 clinical trials in Weiz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Weiz at a glance
435
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

435 trials in Weiz

Open in trial search

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen - Cilag International

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Neurodermatitis

Recruiting

ICP-332 for Adults with Prurigo Nodularis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Soficitinib
  • Sponsor:Innocare Pharma Inc.

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Weiz

What the registry says about research in the country

01 Breast Cancer Research

Clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer, investigating innovative therapeutic approaches for patients with high recurrence risk.

  • Node-positive breast cancer treatment
  • Endocrine therapy optimization
  • Early-stage breast cancer management

Research aims to improve disease-free survival rates through targeted therapeutic interventions.

02 Endocrine Therapy Studies

Investigating the effectiveness of elacestrant compared to standard endocrine treatments for breast cancer patients, with a focus on improving long-term outcomes.

  • Comparative treatment efficacy
  • Invasive cancer-free survival
  • Gender-inclusive research

Studies evaluate novel therapeutic approaches for both women and men with hormone-sensitive breast cancer.

03 Advanced Treatment Protocols

Evaluation of palbociclib in combination with standard endocrine therapy, exploring enhanced treatment strategies for early-stage breast cancer.

  • Combination therapy assessment
  • Long-term treatment outcomes
  • Risk reduction strategies

Research focuses on improving standard treatment protocols through innovative drug combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.